The history of Hemophilia Treatments Centers (HTCs) in the United States dates back to the early 20th century. At that time, people with genetic bleeding disorders faced limited treatment options and a poor prognosis. In the 1940s, advances in blood transfusions and plasma-based therapies improved the survival of people with hemophilia.
In the mid-20th century, HTCs were established in major cities across the United States. These centers brought together multidisciplinary teams of healthcare professionals to provide comprehensive care to people with hemophilia, including regular infusions of clotting factor concentrate to manage bleeding episodes.
In the 1980s and 1990s, the advent of recombinant clotting factor concentrates revolutionized hemophilia treatment. In the wake of the tragedy of the bad blood crisis, these products, which were derived from genetically engineered cells instead of donated plasma, were safer, more reliable, and widely available.
Today, HTCs continue to play a critical role in providing care and support to people with bleeding disorders. They offer a wide range of services, including access to cutting-edge treatments, genetic counseling, physical therapy, and support groups. Many centers also participate in clinical trials to evaluate new treatments and improve care for people with hemophilia.
